Hanniffy et al., 2004 - Google Patents
Potential and opportunities for use of recombinant lactic acid bacteria in human healthHanniffy et al., 2004
View PDF- Document ID
- 698381656139204583
- Author
- Hanniffy S
- Wiedermann U
- Repa A
- Mercenier A
- Daniel C
- Fioramonti J
- Tlaskolova H
- Kozakova H
- Israelsen H
- Madsen S
- Vrang A
- Hols P
- Delcour J
- Bron P
- Kleerebezem M
- Wells J
- Publication year
- Publication venue
- Adv Appl Microbiol
External Links
Snippet
Dietary lactic acid bacteria (LAB) are mostly known for their widespread use in the production and preservation of fermented foods and as such have obtained the ''generally regarded as safe''(GRAS) status within the food industry (Adams and Marteau, 1995). Some …
- 241000894006 Bacteria 0 title abstract description 61
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Micro-organisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—PROCESSES USING MICRO-ORGANISMS
- C12R1/00—Processes using micro-organisms
- C12R1/01—Processes using micro-organisms using bacteria or actinomycetales
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Micro-organisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving micro-organisms or compositions thereof; Processes of preparing or isolating a composition containing a micro-organism; Culture media therefor
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Hanniffy et al. | Potential and opportunities for use of recombinant lactic acid bacteria in human health | |
KR102624867B1 (en) | Bifidobacterium breve 207-1 and uses thereof | |
DK2134833T3 (en) | Probiotic Bifidobacterium strain | |
Tavares et al. | Novel strategies for efficient production and delivery of live biotherapeutics and biotechnological uses of Lactococcus lactis: the lactic acid bacterium model | |
EP2134835B1 (en) | Probiotic bifidobacterium strains | |
Wen et al. | Immunization with recombinant Lactobacillus casei strains producing K99, K88 fimbrial protein protects mice against enterotoxigenic Escherichia coli | |
US20060121015A1 (en) | Probiotic bifidobacterium strains | |
AU2015200833A1 (en) | Probiotic bifidobacterium strain | |
JP6669703B2 (en) | Modified Gram-positive bacteria and uses thereof | |
Kneifel et al. | Probiotics and health claims | |
US10849939B2 (en) | Probiotic formulation | |
US20120207713A1 (en) | Probiotic bifidobacterium strains | |
Van Zyl | Gastrointestinal persistence of the probiotic bacteria Lactobacillus plantarum 423 and Enterococcus mundtii ST4SA, and their anti-listerial activity | |
Chen et al. | Genetic operation system of lactic acid bacteria and its applications | |
Bamunuarachchige et al. | Genetic engineering of probiotic microorganisms | |
Renault | Genetically modified lactic acid bacteria | |
Åvall-Jääskeläinen | Characterization and applications of Lactobacillus brevis S-layer proteins and evaluation of Lactococcus lactis as a porcine cytokine producer | |
Klaenhammer et al. | Genomics of probiotic lactic acid bacteria: Impacts on functional foods | |
Zhang | Intestinal delivery of heterologous peptides with lactobacilli | |
Mercenier | Todd R. Klaenhammer North Carolina State University, Raleigh, North Carolina, USA Willem M. de Vos Wageningen University and Wageningen Center for Food Sciences, Wageningen, The Netherlands | |
HK1141554B (en) | Probiotic bifidobacterium strains | |
HK1141555B (en) | Probiotic bifidobacterium strains | |
IE20080245A1 (en) | Probiotic Bifidobacteria strains | |
IE20080244A1 (en) | Probiotic Bifidobacteria strains |